This site makes use of Javascript, please enable your web browser to allow Javascript. Thank you.

LMG Life Sciences Honors Kaye Scholer With Top Awards in Antitrust and Patent Litigation

September 17, 2015

Five accolades recognize Kaye Scholer’s strong practices and attorneys

At its recent awards ceremony in New York, LMG Life Sciences honored Kaye Scholer with five awards, including the top “Firm of the Year” award in each of the antitrust and patent litigation categories and its Antitrust Litigator of the Year title.

Kaye Scholer received a total of 8 nominations for this year’s awards, which recognize key law firms, lawyers and the innovative work being accomplished throughout the life sciences industry.

Kaye Scholer’s five 2015 LMG Life Sciences awards are:

  • Antitrust Litigation Firm of the Year
    The firm was recognized for its innovative and successful representation of leading pharmaceutical clients Pfizer Inc., Novartis Consumer Health and King Pharmaceuticals, among others, in noteworthy antitrust cases.
  • Patent Litigation Firm of the Year
    LMG recognized our strong patent work in the life sciences sector, which accounts for approximately half of our patent litigation work, in particular our representation of Pfizer (Celebrex and Viagra), Affymetrix, Sequenom, and Acorda.
  • Antitrust Litigator of the Year: Saul Morgenstern
    Partner Saul Morgenstern, chair of Kaye Scholer’s Antitrust practice, was recognized as Antitrust Litigator of the Year.
  • Impact Cases of the Year: Acorda Therapeutics v Mylan Pharmaceuticals
    Kaye Scholer Intellectual Property co-chair Aaron Stiefel led the team that included Sylvia Becker, Daniel DiNapoli and Soumitra Deka in securing a favorable jurisdictional decision for Acorda Therapeutics Inc. in its ANDA-related patent infringement action, Acorda Therapeutics Inc. v. Mylan Pharmaceuticals Inc., in January of this year.
  • Impact Cases of the Year: Clayworth et al v Pfizer et al
    Morgenstern and Aton Arbisser co-led Novartis’ defense in a long-running antitrust action brought against virtually all of the major branded pharmaceutical companies. Morgenstern, Arbisser and Karin Garvey developed the motion for summary judgment on the merits along with a team of co-defendants’ counsel from Arnold & Porter, Cleary Gottlieb Steen & Hamilton, Covington & Burling, Cravath Swaine & Moore, Crowell & Moring, Davis Polk & Wardwell, Hughes Hubbard & Reed, Latham & Watkins, Orrick, Sedgwick and Shepherd Mullen. Morgenstern successfully argued the motion for summary judgment on behalf of the defendants in the Superior Court, and Arbisser defended the victory before the California Court of Appeal,  which resulted in the dismissal of all claims against the 15 brand name prescription drug manufacturer defendants and PhRMA, their trade association.




Also of Interest